Re-treatment with peginterferon-ribavirin and direct antiviral agents of patients with chronic hepatitis C after failure of intensified treatment
10.3760/cma.j.issn.1003-9279.2018.01.014
- VernacularTitle: 慢性丙型肝炎干扰素强化治疗失败患者的PR联合DAA再治疗研究
- Author:
Yao LU
1
;
Hongxiao HAO
;
Ge SHEN
;
Shuling WU
;
Ruyu LIU
;
Leiping HU
;
Min CHANG
;
Weihua CAO
;
Xinyue WANG
;
Chongping RAN
;
Tianlin QI
;
Yunzhong WU
;
Min YANG
;
Lu ZHANG
;
Minghui LI
;
Yao XIE
;
Daozhen XU
Author Information
1. Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
- Publication Type:Journal Article
- Keywords:
Hepatitis C, chronic;
Ribavirin;
Peginterferon;
Direct antiviral agent (DAA)
- From:
Chinese Journal of Experimental and Clinical Virology
2018;32(1):66-69
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the persistent viral response rate (SVR) in patients with refractory chronic hepatitis C after interferon (IFN) (peginterferon 360 μg qw) and ribavirin (PR) therapy failure. The SVR of patients with refractory chronic hepatitis C was improved by PR combined with direct antiviral agents (DAA) and proper extension of the course of therapy was applied.
Methods:Seventeen cases of refractory chronic hepatitis C after IFN(peginterferon 360 μg qw) and ribavirin therapy failure were given PR combined with DAA treatment. The side effects were observed and corresponding adjustments were made on drug dosage, and SVR was recorded.
Results:The 17 cases completed the whole course of treatment with PR combined with DAA for 24 weeks. All the 17 patients obtained rapid viralogical response (RVR) and SVR. After treatment, the SVR rate was 100% in patients including those with virologic relapse, retreated or previously non-responsive patients with refractory chronic hepatitis C. The adverse reaction of PR combined with DAA 24 weeks was generally mild.
Conclusions:The use of PR combined with DAA re-treatment in patients with refractory chronic hepatitis C can achieve SVR and shorten the treatment time. PR combined with DAA re-therapy is one of effective treatments to improve the rate of sustained viral response in patients with refractory chronic hepatitis C.
